nodes	percent_of_prediction	percent_of_DWPC	metapath
Tretinoin—CYP3A7—Paclitaxel—ovarian cancer	0.036	0.123	CbGbCtD
Tretinoin—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.036	0.123	CbGbCtD
Tretinoin—CYP3A5—Paclitaxel—ovarian cancer	0.027	0.0921	CbGbCtD
Tretinoin—CYP3A7—Docetaxel—ovarian cancer	0.026	0.0888	CbGbCtD
Tretinoin—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.026	0.0888	CbGbCtD
Tretinoin—CYP2C8—Paclitaxel—ovarian cancer	0.026	0.0885	CbGbCtD
Tretinoin—CYP3A4—Topotecan—ovarian cancer	0.0213	0.0725	CbGbCtD
Tretinoin—CYP3A5—Docetaxel—ovarian cancer	0.0195	0.0666	CbGbCtD
Tretinoin—CYP2B6—Doxorubicin—ovarian cancer	0.0185	0.063	CbGbCtD
Tretinoin—CYP2C9—Paclitaxel—ovarian cancer	0.0181	0.0618	CbGbCtD
Tretinoin—CYP3A4—Vinorelbine—ovarian cancer	0.015	0.0511	CbGbCtD
Tretinoin—CYP3A4—Paclitaxel—ovarian cancer	0.0105	0.0359	CbGbCtD
Tretinoin—ALDH1A1—oviduct—ovarian cancer	0.0079	0.0441	CbGeAlD
Tretinoin—CYP3A4—Docetaxel—ovarian cancer	0.00762	0.026	CbGbCtD
Tretinoin—CYP3A4—Doxorubicin—ovarian cancer	0.00568	0.0194	CbGbCtD
Tretinoin—GPRC5A—female reproductive system—ovarian cancer	0.00522	0.0292	CbGeAlD
Tretinoin—RARRES1—myometrium—ovarian cancer	0.00453	0.0253	CbGeAlD
Tretinoin—RARRES1—uterine cervix—ovarian cancer	0.00353	0.0197	CbGeAlD
Tretinoin—RARRES1—decidua—ovarian cancer	0.00336	0.0188	CbGeAlD
Tretinoin—ALDH1A2—embryo—ovarian cancer	0.00334	0.0187	CbGeAlD
Tretinoin—CRABP1—embryo—ovarian cancer	0.00323	0.018	CbGeAlD
Tretinoin—RARRES1—endometrium—ovarian cancer	0.00319	0.0178	CbGeAlD
Tretinoin—CRABP2—myometrium—ovarian cancer	0.00303	0.0169	CbGeAlD
Tretinoin—RARRES1—uterus—ovarian cancer	0.00294	0.0164	CbGeAlD
Tretinoin—CRABP2—embryo—ovarian cancer	0.00292	0.0163	CbGeAlD
Tretinoin—ALDH1A1—Vinblastine—Vinorelbine—ovarian cancer	0.00284	0.461	CbGdCrCtD
Tretinoin—RARRES1—female reproductive system—ovarian cancer	0.00264	0.0147	CbGeAlD
Tretinoin—CRABP1—uterine cervix—ovarian cancer	0.00261	0.0146	CbGeAlD
Tretinoin—ALDH1A2—decidua—ovarian cancer	0.00258	0.0144	CbGeAlD
Tretinoin—NR0B1—gonad—ovarian cancer	0.00255	0.0142	CbGeAlD
Tretinoin—ALDH1A1—myometrium—ovarian cancer	0.00253	0.0141	CbGeAlD
Tretinoin—ALDH1A2—endometrium—ovarian cancer	0.00245	0.0137	CbGeAlD
Tretinoin—ALDH1A1—embryo—ovarian cancer	0.00243	0.0136	CbGeAlD
Tretinoin—RARRES1—female gonad—ovarian cancer	0.0024	0.0134	CbGeAlD
Tretinoin—RARRES1—vagina—ovarian cancer	0.00239	0.0133	CbGeAlD
Tretinoin—CRABP2—uterine cervix—ovarian cancer	0.00236	0.0132	CbGeAlD
Tretinoin—NR0B1—female reproductive system—ovarian cancer	0.00227	0.0127	CbGeAlD
Tretinoin—ALDH1A2—gonad—ovarian cancer	0.00227	0.0127	CbGeAlD
Tretinoin—ALDH1A2—uterus—ovarian cancer	0.00225	0.0126	CbGeAlD
Tretinoin—CRABP2—decidua—ovarian cancer	0.00225	0.0126	CbGeAlD
Tretinoin—CRABP1—gonad—ovarian cancer	0.00219	0.0122	CbGeAlD
Tretinoin—CRABP2—endometrium—ovarian cancer	0.00213	0.0119	CbGeAlD
Tretinoin—RARRES1—testis—ovarian cancer	0.00213	0.0119	CbGeAlD
Tretinoin—RARA—myometrium—ovarian cancer	0.00208	0.0116	CbGeAlD
Tretinoin—NR0B1—female gonad—ovarian cancer	0.00207	0.0115	CbGeAlD
Tretinoin—ALDH1A2—female reproductive system—ovarian cancer	0.00203	0.0113	CbGeAlD
Tretinoin—CRABP2—gonad—ovarian cancer	0.00198	0.0111	CbGeAlD
Tretinoin—ALDH1A1—uterine cervix—ovarian cancer	0.00197	0.011	CbGeAlD
Tretinoin—CRABP1—female reproductive system—ovarian cancer	0.00196	0.0109	CbGeAlD
Tretinoin—ALDH1A1—decidua—ovarian cancer	0.00187	0.0105	CbGeAlD
Tretinoin—RXRB—decidua—ovarian cancer	0.00185	0.0103	CbGeAlD
Tretinoin—ALDH1A2—female gonad—ovarian cancer	0.00184	0.0103	CbGeAlD
Tretinoin—NR0B1—testis—ovarian cancer	0.00184	0.0102	CbGeAlD
Tretinoin—ALDH1A2—vagina—ovarian cancer	0.00183	0.0102	CbGeAlD
Tretinoin—ALDH1A1—endometrium—ovarian cancer	0.00178	0.00993	CbGeAlD
Tretinoin—CRABP1—vagina—ovarian cancer	0.00177	0.00987	CbGeAlD
Tretinoin—CYP4A11—vagina—ovarian cancer	0.00177	0.00987	CbGeAlD
Tretinoin—CRABP2—female reproductive system—ovarian cancer	0.00177	0.00987	CbGeAlD
Tretinoin—RXRA—female reproductive system—ovarian cancer	0.00176	0.00983	CbGeAlD
Tretinoin—CYP2C18—uterine cervix—ovarian cancer	0.00173	0.00965	CbGeAlD
Tretinoin—ALDH1A1—Idarubicin—Epirubicin—ovarian cancer	0.00172	0.28	CbGdCrCtD
Tretinoin—ALDH1A1—gonad—ovarian cancer	0.00165	0.00921	CbGeAlD
Tretinoin—RARG—decidua—ovarian cancer	0.00164	0.00916	CbGeAlD
Tretinoin—ALDH1A1—uterus—ovarian cancer	0.00164	0.00915	CbGeAlD
Tretinoin—ALDH1A2—testis—ovarian cancer	0.00164	0.00913	CbGeAlD
Tretinoin—CRABP2—female gonad—ovarian cancer	0.00161	0.00898	CbGeAlD
Tretinoin—RXRA—female gonad—ovarian cancer	0.0016	0.00894	CbGeAlD
Tretinoin—CRABP2—vagina—ovarian cancer	0.0016	0.00893	CbGeAlD
Tretinoin—ALDH1A1—Idarubicin—Doxorubicin—ovarian cancer	0.00159	0.259	CbGdCrCtD
Tretinoin—RARB—female reproductive system—ovarian cancer	0.00158	0.00883	CbGeAlD
Tretinoin—CRABP1—testis—ovarian cancer	0.00158	0.00881	CbGeAlD
Tretinoin—RARRES1—lymph node—ovarian cancer	0.00155	0.00863	CbGeAlD
Tretinoin—RARA—decidua—ovarian cancer	0.00154	0.00861	CbGeAlD
Tretinoin—ALDH1A1—female reproductive system—ovarian cancer	0.00147	0.00823	CbGeAlD
Tretinoin—RARA—endometrium—ovarian cancer	0.00146	0.00817	CbGeAlD
Tretinoin—RARB—female gonad—ovarian cancer	0.00144	0.00803	CbGeAlD
Tretinoin—RARG—uterus—ovarian cancer	0.00144	0.00801	CbGeAlD
Tretinoin—RARB—vagina—ovarian cancer	0.00143	0.00798	CbGeAlD
Tretinoin—CRABP2—testis—ovarian cancer	0.00143	0.00797	CbGeAlD
Tretinoin—ALDH1A1—bone marrow—ovarian cancer	0.00139	0.00777	CbGeAlD
Tretinoin—RARA—gonad—ovarian cancer	0.00136	0.00758	CbGeAlD
Tretinoin—RARA—uterus—ovarian cancer	0.00135	0.00753	CbGeAlD
Tretinoin—ALDH1A1—female gonad—ovarian cancer	0.00134	0.00748	CbGeAlD
Tretinoin—ALDH1A1—vagina—ovarian cancer	0.00133	0.00744	CbGeAlD
Tretinoin—RXRB—female gonad—ovarian cancer	0.00132	0.00738	CbGeAlD
Tretinoin—RXRB—vagina—ovarian cancer	0.00131	0.00734	CbGeAlD
Tretinoin—RARG—female reproductive system—ovarian cancer	0.00129	0.0072	CbGeAlD
Tretinoin—RXRG—testis—ovarian cancer	0.00125	0.00696	CbGeAlD
Tretinoin—RARA—female reproductive system—ovarian cancer	0.00121	0.00677	CbGeAlD
Tretinoin—ALDH1A1—testis—ovarian cancer	0.00119	0.00664	CbGeAlD
Tretinoin—ALDH1A2—lymph node—ovarian cancer	0.00119	0.00662	CbGeAlD
Tretinoin—RARG—female gonad—ovarian cancer	0.00117	0.00655	CbGeAlD
Tretinoin—RXRB—testis—ovarian cancer	0.00117	0.00655	CbGeAlD
Tretinoin—CYP2C18—vagina—ovarian cancer	0.00117	0.00654	CbGeAlD
Tretinoin—RARG—vagina—ovarian cancer	0.00117	0.00651	CbGeAlD
Tretinoin—RARA—bone marrow—ovarian cancer	0.00115	0.00639	CbGeAlD
Tretinoin—RARA—female gonad—ovarian cancer	0.0011	0.00616	CbGeAlD
Tretinoin—RARG—testis—ovarian cancer	0.00104	0.00581	CbGeAlD
Tretinoin—RARA—testis—ovarian cancer	0.000979	0.00546	CbGeAlD
Tretinoin—RARB—lymph node—ovarian cancer	0.000925	0.00516	CbGeAlD
Tretinoin—ALDH1A1—lymph node—ovarian cancer	0.000862	0.00481	CbGeAlD
Tretinoin—CYP2A6—vagina—ovarian cancer	0.000774	0.00432	CbGeAlD
Tretinoin—RARG—lymph node—ovarian cancer	0.000755	0.00421	CbGeAlD
Tretinoin—RARA—lymph node—ovarian cancer	0.00071	0.00396	CbGeAlD
Tretinoin—CYP1A1—epithelium—ovarian cancer	0.000597	0.00333	CbGeAlD
Tretinoin—CYP1A1—uterine cervix—ovarian cancer	0.000592	0.0033	CbGeAlD
Tretinoin—CYP2C8—endometrium—ovarian cancer	0.00058	0.00324	CbGeAlD
Tretinoin—CYP3A5—uterine cervix—ovarian cancer	0.000579	0.00323	CbGeAlD
Tretinoin—CYP1A1—uterus—ovarian cancer	0.000493	0.00275	CbGeAlD
Tretinoin—CYP2B6—gonad—ovarian cancer	0.000483	0.00269	CbGeAlD
Tretinoin—CYP2C8—female reproductive system—ovarian cancer	0.000481	0.00268	CbGeAlD
Tretinoin—CYP1A1—female reproductive system—ovarian cancer	0.000444	0.00248	CbGeAlD
Tretinoin—CYP2C8—vagina—ovarian cancer	0.000435	0.00243	CbGeAlD
Tretinoin—CYP2B6—female reproductive system—ovarian cancer	0.000431	0.00241	CbGeAlD
Tretinoin—CYP2C9—female reproductive system—ovarian cancer	0.000427	0.00238	CbGeAlD
Tretinoin—CYP1A1—female gonad—ovarian cancer	0.000404	0.00225	CbGeAlD
Tretinoin—CYP1A1—vagina—ovarian cancer	0.000401	0.00224	CbGeAlD
Tretinoin—CYP3A5—female gonad—ovarian cancer	0.000395	0.0022	CbGeAlD
Tretinoin—CYP3A5—vagina—ovarian cancer	0.000392	0.00219	CbGeAlD
Tretinoin—CYP2B6—vagina—ovarian cancer	0.00039	0.00218	CbGeAlD
Tretinoin—CYP2C8—testis—ovarian cancer	0.000388	0.00216	CbGeAlD
Tretinoin—CYP2B6—testis—ovarian cancer	0.000348	0.00194	CbGeAlD
Tretinoin—CYP3A4—female reproductive system—ovarian cancer	0.000326	0.00182	CbGeAlD
Tretinoin—CYP1A1—lymph node—ovarian cancer	0.00026	0.00145	CbGeAlD
Tretinoin—Dyspepsia—Paclitaxel—ovarian cancer	0.000113	0.000349	CcSEcCtD
Tretinoin—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000113	0.000348	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000113	0.000348	CcSEcCtD
Tretinoin—Stomatitis—Epirubicin—ovarian cancer	0.000112	0.000346	CcSEcCtD
Tretinoin—Urinary tract infection—Epirubicin—ovarian cancer	0.000112	0.000345	CcSEcCtD
Tretinoin—Conjunctivitis—Epirubicin—ovarian cancer	0.000112	0.000345	CcSEcCtD
Tretinoin—Neutropenia—Doxorubicin—ovarian cancer	0.000112	0.000345	CcSEcCtD
Tretinoin—Dysuria—Doxorubicin—ovarian cancer	0.000112	0.000345	CcSEcCtD
Tretinoin—Decreased appetite—Paclitaxel—ovarian cancer	0.000112	0.000344	CcSEcCtD
Tretinoin—Dry mouth—Docetaxel—ovarian cancer	0.000111	0.000342	CcSEcCtD
Tretinoin—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000111	0.000342	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000111	0.000342	CcSEcCtD
Tretinoin—Fatigue—Paclitaxel—ovarian cancer	0.000111	0.000341	CcSEcCtD
Tretinoin—Sweating—Epirubicin—ovarian cancer	0.00011	0.00034	CcSEcCtD
Tretinoin—Pollakiuria—Doxorubicin—ovarian cancer	0.00011	0.00034	CcSEcCtD
Tretinoin—Constipation—Paclitaxel—ovarian cancer	0.00011	0.000339	CcSEcCtD
Tretinoin—Pain—Paclitaxel—ovarian cancer	0.00011	0.000339	CcSEcCtD
Tretinoin—Haematuria—Epirubicin—ovarian cancer	0.00011	0.000339	CcSEcCtD
Tretinoin—Confusional state—Docetaxel—ovarian cancer	0.00011	0.000338	CcSEcCtD
Tretinoin—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000109	0.000336	CcSEcCtD
Tretinoin—Oedema—Docetaxel—ovarian cancer	0.000109	0.000336	CcSEcCtD
Tretinoin—Anaphylactic shock—Docetaxel—ovarian cancer	0.000109	0.000336	CcSEcCtD
Tretinoin—Weight increased—Doxorubicin—ovarian cancer	0.000109	0.000335	CcSEcCtD
Tretinoin—Epistaxis—Epirubicin—ovarian cancer	0.000109	0.000335	CcSEcCtD
Tretinoin—Infection—Docetaxel—ovarian cancer	0.000108	0.000334	CcSEcCtD
Tretinoin—Weight decreased—Doxorubicin—ovarian cancer	0.000108	0.000333	CcSEcCtD
Tretinoin—Sinusitis—Epirubicin—ovarian cancer	0.000108	0.000333	CcSEcCtD
Tretinoin—Agranulocytosis—Epirubicin—ovarian cancer	0.000108	0.000331	CcSEcCtD
Tretinoin—Pneumonia—Doxorubicin—ovarian cancer	0.000107	0.00033	CcSEcCtD
Tretinoin—Shock—Docetaxel—ovarian cancer	0.000107	0.00033	CcSEcCtD
Tretinoin—Nervous system disorder—Docetaxel—ovarian cancer	0.000107	0.000329	CcSEcCtD
Tretinoin—Thrombocytopenia—Docetaxel—ovarian cancer	0.000107	0.000329	CcSEcCtD
Tretinoin—Infestation NOS—Doxorubicin—ovarian cancer	0.000107	0.000328	CcSEcCtD
Tretinoin—Infestation—Doxorubicin—ovarian cancer	0.000107	0.000328	CcSEcCtD
Tretinoin—Drowsiness—Doxorubicin—ovarian cancer	0.000107	0.000328	CcSEcCtD
Tretinoin—Tachycardia—Docetaxel—ovarian cancer	0.000106	0.000328	CcSEcCtD
Tretinoin—Feeling abnormal—Paclitaxel—ovarian cancer	0.000106	0.000326	CcSEcCtD
Tretinoin—Skin disorder—Docetaxel—ovarian cancer	0.000106	0.000326	CcSEcCtD
Tretinoin—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000106	0.000326	CcSEcCtD
Tretinoin—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000105	0.000324	CcSEcCtD
Tretinoin—Renal failure—Doxorubicin—ovarian cancer	0.000105	0.000323	CcSEcCtD
Tretinoin—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000104	0.000322	CcSEcCtD
Tretinoin—Haemoglobin—Epirubicin—ovarian cancer	0.000104	0.00032	CcSEcCtD
Tretinoin—Stomatitis—Doxorubicin—ovarian cancer	0.000104	0.00032	CcSEcCtD
Tretinoin—Anorexia—Docetaxel—ovarian cancer	0.000104	0.00032	CcSEcCtD
Tretinoin—Urinary tract infection—Doxorubicin—ovarian cancer	0.000104	0.000319	CcSEcCtD
Tretinoin—Conjunctivitis—Doxorubicin—ovarian cancer	0.000104	0.000319	CcSEcCtD
Tretinoin—Haemorrhage—Epirubicin—ovarian cancer	0.000103	0.000319	CcSEcCtD
Tretinoin—Hepatitis—Epirubicin—ovarian cancer	0.000103	0.000319	CcSEcCtD
Tretinoin—Hypoaesthesia—Epirubicin—ovarian cancer	0.000103	0.000317	CcSEcCtD
Tretinoin—Pharyngitis—Epirubicin—ovarian cancer	0.000103	0.000316	CcSEcCtD
Tretinoin—Sweating—Doxorubicin—ovarian cancer	0.000102	0.000315	CcSEcCtD
Tretinoin—Urinary tract disorder—Epirubicin—ovarian cancer	0.000102	0.000315	CcSEcCtD
Tretinoin—Urticaria—Paclitaxel—ovarian cancer	0.000102	0.000315	CcSEcCtD
Tretinoin—Oedema peripheral—Epirubicin—ovarian cancer	0.000102	0.000314	CcSEcCtD
Tretinoin—Hypotension—Docetaxel—ovarian cancer	0.000102	0.000314	CcSEcCtD
Tretinoin—Haematuria—Doxorubicin—ovarian cancer	0.000102	0.000313	CcSEcCtD
Tretinoin—Body temperature increased—Paclitaxel—ovarian cancer	0.000102	0.000313	CcSEcCtD
Tretinoin—Abdominal pain—Paclitaxel—ovarian cancer	0.000102	0.000313	CcSEcCtD
Tretinoin—Urethral disorder—Epirubicin—ovarian cancer	0.000101	0.000312	CcSEcCtD
Tretinoin—Epistaxis—Doxorubicin—ovarian cancer	0.000101	0.00031	CcSEcCtD
Tretinoin—Sinusitis—Doxorubicin—ovarian cancer	0.0001	0.000308	CcSEcCtD
Tretinoin—Visual impairment—Epirubicin—ovarian cancer	9.97e-05	0.000307	CcSEcCtD
Tretinoin—Agranulocytosis—Doxorubicin—ovarian cancer	9.95e-05	0.000307	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Docetaxel—ovarian cancer	9.93e-05	0.000306	CcSEcCtD
Tretinoin—Insomnia—Docetaxel—ovarian cancer	9.85e-05	0.000304	CcSEcCtD
Tretinoin—Paraesthesia—Docetaxel—ovarian cancer	9.78e-05	0.000301	CcSEcCtD
Tretinoin—Erythema multiforme—Epirubicin—ovarian cancer	9.78e-05	0.000301	CcSEcCtD
Tretinoin—Dyspnoea—Docetaxel—ovarian cancer	9.71e-05	0.000299	CcSEcCtD
Tretinoin—Somnolence—Docetaxel—ovarian cancer	9.68e-05	0.000298	CcSEcCtD
Tretinoin—Eye disorder—Epirubicin—ovarian cancer	9.67e-05	0.000298	CcSEcCtD
Tretinoin—Tinnitus—Epirubicin—ovarian cancer	9.64e-05	0.000297	CcSEcCtD
Tretinoin—Haemoglobin—Doxorubicin—ovarian cancer	9.62e-05	0.000296	CcSEcCtD
Tretinoin—Flushing—Epirubicin—ovarian cancer	9.6e-05	0.000296	CcSEcCtD
Tretinoin—Dyspepsia—Docetaxel—ovarian cancer	9.59e-05	0.000296	CcSEcCtD
Tretinoin—Haemorrhage—Doxorubicin—ovarian cancer	9.57e-05	0.000295	CcSEcCtD
Tretinoin—Hepatitis—Doxorubicin—ovarian cancer	9.57e-05	0.000295	CcSEcCtD
Tretinoin—Hypoaesthesia—Doxorubicin—ovarian cancer	9.52e-05	0.000293	CcSEcCtD
Tretinoin—Pharyngitis—Doxorubicin—ovarian cancer	9.5e-05	0.000293	CcSEcCtD
Tretinoin—Decreased appetite—Docetaxel—ovarian cancer	9.47e-05	0.000292	CcSEcCtD
Tretinoin—Hypersensitivity—Paclitaxel—ovarian cancer	9.47e-05	0.000292	CcSEcCtD
Tretinoin—Urinary tract disorder—Doxorubicin—ovarian cancer	9.45e-05	0.000291	CcSEcCtD
Tretinoin—Oedema peripheral—Doxorubicin—ovarian cancer	9.43e-05	0.000291	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Docetaxel—ovarian cancer	9.41e-05	0.00029	CcSEcCtD
Tretinoin—Fatigue—Docetaxel—ovarian cancer	9.39e-05	0.000289	CcSEcCtD
Tretinoin—Angiopathy—Epirubicin—ovarian cancer	9.38e-05	0.000289	CcSEcCtD
Tretinoin—Urethral disorder—Doxorubicin—ovarian cancer	9.38e-05	0.000289	CcSEcCtD
Tretinoin—Constipation—Docetaxel—ovarian cancer	9.32e-05	0.000287	CcSEcCtD
Tretinoin—Pain—Docetaxel—ovarian cancer	9.32e-05	0.000287	CcSEcCtD
Tretinoin—Chills—Epirubicin—ovarian cancer	9.28e-05	0.000286	CcSEcCtD
Tretinoin—Arrhythmia—Epirubicin—ovarian cancer	9.24e-05	0.000285	CcSEcCtD
Tretinoin—Visual impairment—Doxorubicin—ovarian cancer	9.22e-05	0.000284	CcSEcCtD
Tretinoin—Asthenia—Paclitaxel—ovarian cancer	9.22e-05	0.000284	CcSEcCtD
Tretinoin—Alopecia—Epirubicin—ovarian cancer	9.14e-05	0.000282	CcSEcCtD
Tretinoin—Pruritus—Paclitaxel—ovarian cancer	9.09e-05	0.00028	CcSEcCtD
Tretinoin—Mental disorder—Epirubicin—ovarian cancer	9.06e-05	0.000279	CcSEcCtD
Tretinoin—Erythema multiforme—Doxorubicin—ovarian cancer	9.05e-05	0.000279	CcSEcCtD
Tretinoin—Erythema—Epirubicin—ovarian cancer	9e-05	0.000277	CcSEcCtD
Tretinoin—Malnutrition—Epirubicin—ovarian cancer	9e-05	0.000277	CcSEcCtD
Tretinoin—Feeling abnormal—Docetaxel—ovarian cancer	8.98e-05	0.000277	CcSEcCtD
Tretinoin—Eye disorder—Doxorubicin—ovarian cancer	8.94e-05	0.000276	CcSEcCtD
Tretinoin—Tinnitus—Doxorubicin—ovarian cancer	8.92e-05	0.000275	CcSEcCtD
Tretinoin—Gastrointestinal pain—Docetaxel—ovarian cancer	8.91e-05	0.000275	CcSEcCtD
Tretinoin—Flushing—Doxorubicin—ovarian cancer	8.88e-05	0.000274	CcSEcCtD
Tretinoin—Flatulence—Epirubicin—ovarian cancer	8.87e-05	0.000273	CcSEcCtD
Tretinoin—Tension—Epirubicin—ovarian cancer	8.83e-05	0.000272	CcSEcCtD
Tretinoin—Diarrhoea—Paclitaxel—ovarian cancer	8.79e-05	0.000271	CcSEcCtD
Tretinoin—Nervousness—Epirubicin—ovarian cancer	8.74e-05	0.000269	CcSEcCtD
Tretinoin—Back pain—Epirubicin—ovarian cancer	8.71e-05	0.000268	CcSEcCtD
Tretinoin—Angiopathy—Doxorubicin—ovarian cancer	8.68e-05	0.000268	CcSEcCtD
Tretinoin—Abdominal pain—Docetaxel—ovarian cancer	8.61e-05	0.000265	CcSEcCtD
Tretinoin—Body temperature increased—Docetaxel—ovarian cancer	8.61e-05	0.000265	CcSEcCtD
Tretinoin—Chills—Doxorubicin—ovarian cancer	8.59e-05	0.000265	CcSEcCtD
Tretinoin—Arrhythmia—Doxorubicin—ovarian cancer	8.55e-05	0.000263	CcSEcCtD
Tretinoin—Dizziness—Paclitaxel—ovarian cancer	8.5e-05	0.000262	CcSEcCtD
Tretinoin—Vision blurred—Epirubicin—ovarian cancer	8.49e-05	0.000261	CcSEcCtD
Tretinoin—Alopecia—Doxorubicin—ovarian cancer	8.46e-05	0.000261	CcSEcCtD
Tretinoin—Mental disorder—Doxorubicin—ovarian cancer	8.38e-05	0.000258	CcSEcCtD
Tretinoin—Ill-defined disorder—Epirubicin—ovarian cancer	8.35e-05	0.000257	CcSEcCtD
Tretinoin—Malnutrition—Doxorubicin—ovarian cancer	8.33e-05	0.000257	CcSEcCtD
Tretinoin—Erythema—Doxorubicin—ovarian cancer	8.33e-05	0.000257	CcSEcCtD
Tretinoin—Anaemia—Epirubicin—ovarian cancer	8.32e-05	0.000256	CcSEcCtD
Tretinoin—Agitation—Epirubicin—ovarian cancer	8.27e-05	0.000255	CcSEcCtD
Tretinoin—Flatulence—Doxorubicin—ovarian cancer	8.21e-05	0.000253	CcSEcCtD
Tretinoin—Tension—Doxorubicin—ovarian cancer	8.17e-05	0.000252	CcSEcCtD
Tretinoin—Vomiting—Paclitaxel—ovarian cancer	8.17e-05	0.000252	CcSEcCtD
Tretinoin—Malaise—Epirubicin—ovarian cancer	8.12e-05	0.00025	CcSEcCtD
Tretinoin—Rash—Paclitaxel—ovarian cancer	8.1e-05	0.00025	CcSEcCtD
Tretinoin—Dermatitis—Paclitaxel—ovarian cancer	8.1e-05	0.000249	CcSEcCtD
Tretinoin—Nervousness—Doxorubicin—ovarian cancer	8.09e-05	0.000249	CcSEcCtD
Tretinoin—Syncope—Epirubicin—ovarian cancer	8.07e-05	0.000249	CcSEcCtD
Tretinoin—Back pain—Doxorubicin—ovarian cancer	8.06e-05	0.000248	CcSEcCtD
Tretinoin—Headache—Paclitaxel—ovarian cancer	8.05e-05	0.000248	CcSEcCtD
Tretinoin—Hypersensitivity—Docetaxel—ovarian cancer	8.03e-05	0.000247	CcSEcCtD
Tretinoin—Palpitations—Epirubicin—ovarian cancer	7.96e-05	0.000245	CcSEcCtD
Tretinoin—Loss of consciousness—Epirubicin—ovarian cancer	7.91e-05	0.000244	CcSEcCtD
Tretinoin—Cough—Epirubicin—ovarian cancer	7.86e-05	0.000242	CcSEcCtD
Tretinoin—Vision blurred—Doxorubicin—ovarian cancer	7.85e-05	0.000242	CcSEcCtD
Tretinoin—Asthenia—Docetaxel—ovarian cancer	7.82e-05	0.000241	CcSEcCtD
Tretinoin—Convulsion—Epirubicin—ovarian cancer	7.8e-05	0.00024	CcSEcCtD
Tretinoin—Hypertension—Epirubicin—ovarian cancer	7.77e-05	0.00024	CcSEcCtD
Tretinoin—Ill-defined disorder—Doxorubicin—ovarian cancer	7.73e-05	0.000238	CcSEcCtD
Tretinoin—Pruritus—Docetaxel—ovarian cancer	7.71e-05	0.000238	CcSEcCtD
Tretinoin—Anaemia—Doxorubicin—ovarian cancer	7.7e-05	0.000237	CcSEcCtD
Tretinoin—Myalgia—Epirubicin—ovarian cancer	7.67e-05	0.000236	CcSEcCtD
Tretinoin—Arthralgia—Epirubicin—ovarian cancer	7.67e-05	0.000236	CcSEcCtD
Tretinoin—Chest pain—Epirubicin—ovarian cancer	7.67e-05	0.000236	CcSEcCtD
Tretinoin—Agitation—Doxorubicin—ovarian cancer	7.66e-05	0.000236	CcSEcCtD
Tretinoin—Anxiety—Epirubicin—ovarian cancer	7.64e-05	0.000235	CcSEcCtD
Tretinoin—Nausea—Paclitaxel—ovarian cancer	7.63e-05	0.000235	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	7.61e-05	0.000235	CcSEcCtD
Tretinoin—Discomfort—Epirubicin—ovarian cancer	7.57e-05	0.000233	CcSEcCtD
Tretinoin—Malaise—Doxorubicin—ovarian cancer	7.51e-05	0.000231	CcSEcCtD
Tretinoin—Dry mouth—Epirubicin—ovarian cancer	7.5e-05	0.000231	CcSEcCtD
Tretinoin—Syncope—Doxorubicin—ovarian cancer	7.47e-05	0.00023	CcSEcCtD
Tretinoin—Diarrhoea—Docetaxel—ovarian cancer	7.45e-05	0.00023	CcSEcCtD
Tretinoin—Confusional state—Epirubicin—ovarian cancer	7.41e-05	0.000228	CcSEcCtD
Tretinoin—Palpitations—Doxorubicin—ovarian cancer	7.36e-05	0.000227	CcSEcCtD
Tretinoin—Anaphylactic shock—Epirubicin—ovarian cancer	7.35e-05	0.000226	CcSEcCtD
Tretinoin—Oedema—Epirubicin—ovarian cancer	7.35e-05	0.000226	CcSEcCtD
Tretinoin—Loss of consciousness—Doxorubicin—ovarian cancer	7.32e-05	0.000226	CcSEcCtD
Tretinoin—Infection—Epirubicin—ovarian cancer	7.3e-05	0.000225	CcSEcCtD
Tretinoin—Cough—Doxorubicin—ovarian cancer	7.27e-05	0.000224	CcSEcCtD
Tretinoin—Shock—Epirubicin—ovarian cancer	7.23e-05	0.000223	CcSEcCtD
Tretinoin—Convulsion—Doxorubicin—ovarian cancer	7.22e-05	0.000222	CcSEcCtD
Tretinoin—Nervous system disorder—Epirubicin—ovarian cancer	7.21e-05	0.000222	CcSEcCtD
Tretinoin—Dizziness—Docetaxel—ovarian cancer	7.2e-05	0.000222	CcSEcCtD
Tretinoin—Thrombocytopenia—Epirubicin—ovarian cancer	7.19e-05	0.000222	CcSEcCtD
Tretinoin—Hypertension—Doxorubicin—ovarian cancer	7.19e-05	0.000222	CcSEcCtD
Tretinoin—Tachycardia—Epirubicin—ovarian cancer	7.17e-05	0.000221	CcSEcCtD
Tretinoin—Skin disorder—Epirubicin—ovarian cancer	7.14e-05	0.00022	CcSEcCtD
Tretinoin—Hyperhidrosis—Epirubicin—ovarian cancer	7.1e-05	0.000219	CcSEcCtD
Tretinoin—Arthralgia—Doxorubicin—ovarian cancer	7.09e-05	0.000219	CcSEcCtD
Tretinoin—Chest pain—Doxorubicin—ovarian cancer	7.09e-05	0.000219	CcSEcCtD
Tretinoin—Myalgia—Doxorubicin—ovarian cancer	7.09e-05	0.000219	CcSEcCtD
Tretinoin—Anxiety—Doxorubicin—ovarian cancer	7.07e-05	0.000218	CcSEcCtD
Tretinoin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	7.04e-05	0.000217	CcSEcCtD
Tretinoin—Discomfort—Doxorubicin—ovarian cancer	7.01e-05	0.000216	CcSEcCtD
Tretinoin—Anorexia—Epirubicin—ovarian cancer	7e-05	0.000216	CcSEcCtD
Tretinoin—Dry mouth—Doxorubicin—ovarian cancer	6.94e-05	0.000214	CcSEcCtD
Tretinoin—Vomiting—Docetaxel—ovarian cancer	6.93e-05	0.000213	CcSEcCtD
Tretinoin—Rash—Docetaxel—ovarian cancer	6.87e-05	0.000212	CcSEcCtD
Tretinoin—Hypotension—Epirubicin—ovarian cancer	6.87e-05	0.000212	CcSEcCtD
Tretinoin—Dermatitis—Docetaxel—ovarian cancer	6.86e-05	0.000211	CcSEcCtD
Tretinoin—Confusional state—Doxorubicin—ovarian cancer	6.86e-05	0.000211	CcSEcCtD
Tretinoin—Headache—Docetaxel—ovarian cancer	6.82e-05	0.00021	CcSEcCtD
Tretinoin—Oedema—Doxorubicin—ovarian cancer	6.8e-05	0.00021	CcSEcCtD
Tretinoin—Anaphylactic shock—Doxorubicin—ovarian cancer	6.8e-05	0.00021	CcSEcCtD
Tretinoin—Infection—Doxorubicin—ovarian cancer	6.75e-05	0.000208	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Epirubicin—ovarian cancer	6.69e-05	0.000206	CcSEcCtD
Tretinoin—Shock—Doxorubicin—ovarian cancer	6.69e-05	0.000206	CcSEcCtD
Tretinoin—Nervous system disorder—Doxorubicin—ovarian cancer	6.67e-05	0.000205	CcSEcCtD
Tretinoin—Thrombocytopenia—Doxorubicin—ovarian cancer	6.66e-05	0.000205	CcSEcCtD
Tretinoin—Insomnia—Epirubicin—ovarian cancer	6.65e-05	0.000205	CcSEcCtD
Tretinoin—Tachycardia—Doxorubicin—ovarian cancer	6.64e-05	0.000204	CcSEcCtD
Tretinoin—Skin disorder—Doxorubicin—ovarian cancer	6.6e-05	0.000204	CcSEcCtD
Tretinoin—Paraesthesia—Epirubicin—ovarian cancer	6.6e-05	0.000203	CcSEcCtD
Tretinoin—Hyperhidrosis—Doxorubicin—ovarian cancer	6.57e-05	0.000203	CcSEcCtD
Tretinoin—Dyspnoea—Epirubicin—ovarian cancer	6.55e-05	0.000202	CcSEcCtD
Tretinoin—Somnolence—Epirubicin—ovarian cancer	6.53e-05	0.000201	CcSEcCtD
Tretinoin—Anorexia—Doxorubicin—ovarian cancer	6.48e-05	0.0002	CcSEcCtD
Tretinoin—Nausea—Docetaxel—ovarian cancer	6.47e-05	0.000199	CcSEcCtD
Tretinoin—Dyspepsia—Epirubicin—ovarian cancer	6.47e-05	0.000199	CcSEcCtD
Tretinoin—Decreased appetite—Epirubicin—ovarian cancer	6.39e-05	0.000197	CcSEcCtD
Tretinoin—Hypotension—Doxorubicin—ovarian cancer	6.35e-05	0.000196	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Epirubicin—ovarian cancer	6.34e-05	0.000195	CcSEcCtD
Tretinoin—Fatigue—Epirubicin—ovarian cancer	6.34e-05	0.000195	CcSEcCtD
Tretinoin—Constipation—Epirubicin—ovarian cancer	6.28e-05	0.000194	CcSEcCtD
Tretinoin—Pain—Epirubicin—ovarian cancer	6.28e-05	0.000194	CcSEcCtD
Tretinoin—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	6.19e-05	0.000191	CcSEcCtD
Tretinoin—Insomnia—Doxorubicin—ovarian cancer	6.15e-05	0.000189	CcSEcCtD
Tretinoin—Paraesthesia—Doxorubicin—ovarian cancer	6.11e-05	0.000188	CcSEcCtD
Tretinoin—Dyspnoea—Doxorubicin—ovarian cancer	6.06e-05	0.000187	CcSEcCtD
Tretinoin—Feeling abnormal—Epirubicin—ovarian cancer	6.06e-05	0.000187	CcSEcCtD
Tretinoin—Somnolence—Doxorubicin—ovarian cancer	6.04e-05	0.000186	CcSEcCtD
Tretinoin—Gastrointestinal pain—Epirubicin—ovarian cancer	6.01e-05	0.000185	CcSEcCtD
Tretinoin—Dyspepsia—Doxorubicin—ovarian cancer	5.98e-05	0.000184	CcSEcCtD
Tretinoin—Decreased appetite—Doxorubicin—ovarian cancer	5.91e-05	0.000182	CcSEcCtD
Tretinoin—Gastrointestinal disorder—Doxorubicin—ovarian cancer	5.87e-05	0.000181	CcSEcCtD
Tretinoin—Fatigue—Doxorubicin—ovarian cancer	5.86e-05	0.000181	CcSEcCtD
Tretinoin—Urticaria—Epirubicin—ovarian cancer	5.84e-05	0.00018	CcSEcCtD
Tretinoin—Pain—Doxorubicin—ovarian cancer	5.81e-05	0.000179	CcSEcCtD
Tretinoin—Constipation—Doxorubicin—ovarian cancer	5.81e-05	0.000179	CcSEcCtD
Tretinoin—Body temperature increased—Epirubicin—ovarian cancer	5.81e-05	0.000179	CcSEcCtD
Tretinoin—Abdominal pain—Epirubicin—ovarian cancer	5.81e-05	0.000179	CcSEcCtD
Tretinoin—Feeling abnormal—Doxorubicin—ovarian cancer	5.6e-05	0.000173	CcSEcCtD
Tretinoin—Gastrointestinal pain—Doxorubicin—ovarian cancer	5.56e-05	0.000171	CcSEcCtD
Tretinoin—Hypersensitivity—Epirubicin—ovarian cancer	5.41e-05	0.000167	CcSEcCtD
Tretinoin—Urticaria—Doxorubicin—ovarian cancer	5.4e-05	0.000166	CcSEcCtD
Tretinoin—Abdominal pain—Doxorubicin—ovarian cancer	5.37e-05	0.000166	CcSEcCtD
Tretinoin—Body temperature increased—Doxorubicin—ovarian cancer	5.37e-05	0.000166	CcSEcCtD
Tretinoin—Asthenia—Epirubicin—ovarian cancer	5.27e-05	0.000162	CcSEcCtD
Tretinoin—Pruritus—Epirubicin—ovarian cancer	5.2e-05	0.00016	CcSEcCtD
Tretinoin—Diarrhoea—Epirubicin—ovarian cancer	5.03e-05	0.000155	CcSEcCtD
Tretinoin—Hypersensitivity—Doxorubicin—ovarian cancer	5.01e-05	0.000154	CcSEcCtD
Tretinoin—Asthenia—Doxorubicin—ovarian cancer	4.88e-05	0.00015	CcSEcCtD
Tretinoin—Dizziness—Epirubicin—ovarian cancer	4.86e-05	0.00015	CcSEcCtD
Tretinoin—Pruritus—Doxorubicin—ovarian cancer	4.81e-05	0.000148	CcSEcCtD
Tretinoin—Vomiting—Epirubicin—ovarian cancer	4.67e-05	0.000144	CcSEcCtD
Tretinoin—Diarrhoea—Doxorubicin—ovarian cancer	4.65e-05	0.000143	CcSEcCtD
Tretinoin—Rash—Epirubicin—ovarian cancer	4.63e-05	0.000143	CcSEcCtD
Tretinoin—Dermatitis—Epirubicin—ovarian cancer	4.63e-05	0.000143	CcSEcCtD
Tretinoin—Headache—Epirubicin—ovarian cancer	4.6e-05	0.000142	CcSEcCtD
Tretinoin—Dizziness—Doxorubicin—ovarian cancer	4.5e-05	0.000139	CcSEcCtD
Tretinoin—Nausea—Epirubicin—ovarian cancer	4.36e-05	0.000134	CcSEcCtD
Tretinoin—Vomiting—Doxorubicin—ovarian cancer	4.32e-05	0.000133	CcSEcCtD
Tretinoin—Rash—Doxorubicin—ovarian cancer	4.29e-05	0.000132	CcSEcCtD
Tretinoin—Dermatitis—Doxorubicin—ovarian cancer	4.28e-05	0.000132	CcSEcCtD
Tretinoin—Headache—Doxorubicin—ovarian cancer	4.26e-05	0.000131	CcSEcCtD
Tretinoin—Nausea—Doxorubicin—ovarian cancer	4.04e-05	0.000124	CcSEcCtD
Tretinoin—RXRA—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.74e-05	0.000139	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—CYTB—ovarian cancer	2.74e-05	0.000139	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—FASN—ovarian cancer	2.72e-05	0.000138	CbGpPWpGaD
Tretinoin—NR0B1—Gene Expression—MAPK3—ovarian cancer	2.69e-05	0.000137	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—SLC5A5—ovarian cancer	2.68e-05	0.000136	CbGpPWpGaD
Tretinoin—RXRA—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.64e-05	0.000134	CbGpPWpGaD
Tretinoin—NR0B1—Gene Expression—MYC—ovarian cancer	2.62e-05	0.000133	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—ERBB2—ovarian cancer	2.61e-05	0.000133	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—CYTB—ovarian cancer	2.59e-05	0.000132	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—SLC2A1—ovarian cancer	2.59e-05	0.000132	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—PPP2R1A—ovarian cancer	2.57e-05	0.000131	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.55e-05	0.000129	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.54e-05	0.000129	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.53e-05	0.000129	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PPP2R1A—ovarian cancer	2.52e-05	0.000128	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.51e-05	0.000127	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—CYP1B1—ovarian cancer	2.48e-05	0.000126	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—FASN—ovarian cancer	2.47e-05	0.000126	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—BRIP1—ovarian cancer	2.45e-05	0.000125	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PPP1CC—ovarian cancer	2.45e-05	0.000125	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—SLC5A5—ovarian cancer	2.43e-05	0.000124	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—BRIP1—ovarian cancer	2.39e-05	0.000122	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PPP1CC—ovarian cancer	2.39e-05	0.000122	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—CYTB—ovarian cancer	2.37e-05	0.000121	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—SLC2A1—ovarian cancer	2.35e-05	0.000119	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—ABCB1—ovarian cancer	2.34e-05	0.000119	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.32e-05	0.000118	CbGpPWpGaD
Tretinoin—RXRA—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.3e-05	0.000117	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—TYMS—ovarian cancer	2.3e-05	0.000117	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—CTNNB1—ovarian cancer	2.28e-05	0.000116	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PPP1CC—ovarian cancer	2.26e-05	0.000115	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—BRIP1—ovarian cancer	2.26e-05	0.000115	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—CYP1B1—ovarian cancer	2.25e-05	0.000114	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—MMP9—ovarian cancer	2.24e-05	0.000114	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—YAP1—ovarian cancer	2.22e-05	0.000113	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PPP2R1A—ovarian cancer	2.2e-05	0.000112	CbGpPWpGaD
Tretinoin—RARG—Gene Expression—MAPK3—ovarian cancer	2.17e-05	0.00011	CbGpPWpGaD
Tretinoin—RARG—Gene Expression—MYC—ovarian cancer	2.11e-05	0.000107	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—BRIP1—ovarian cancer	2.07e-05	0.000105	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PPP1CC—ovarian cancer	2.07e-05	0.000105	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.07e-05	0.000105	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—PIK3CA—ovarian cancer	2.06e-05	0.000105	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—PIK3CA—ovarian cancer	2.06e-05	0.000105	CbGpPWpGaD
Tretinoin—ALDH1A1—Metabolism—PIK3CA—ovarian cancer	2.06e-05	0.000105	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—ABCB1—ovarian cancer	2.04e-05	0.000104	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—YAP1—ovarian cancer	2.04e-05	0.000104	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—VEGFA—ovarian cancer	2.01e-05	0.000102	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—TYMS—ovarian cancer	2.01e-05	0.000102	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PPP2R1A—ovarian cancer	2e-05	0.000101	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—STAT3—ovarian cancer	1.99e-05	0.000101	CbGpPWpGaD
Tretinoin—RXRA—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.99e-05	0.000101	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—NRAS—ovarian cancer	1.99e-05	0.000101	CbGpPWpGaD
Tretinoin—RXRG—Gene Expression—MAPK3—ovarian cancer	1.98e-05	0.000101	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—NME2—ovarian cancer	1.98e-05	0.0001	CbGpPWpGaD
Tretinoin—RXRA—Generic Transcription Pathway—MYC—ovarian cancer	1.96e-05	9.98e-05	CbGpPWpGaD
Tretinoin—RARB—Gene Expression—MAPK3—ovarian cancer	1.95e-05	9.89e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—CYTB—ovarian cancer	1.93e-05	9.82e-05	CbGpPWpGaD
Tretinoin—RXRG—Gene Expression—MYC—ovarian cancer	1.93e-05	9.81e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—MAPK3—ovarian cancer	1.9e-05	9.66e-05	CbGpPWpGaD
Tretinoin—RARB—Gene Expression—MYC—ovarian cancer	1.89e-05	9.62e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.89e-05	9.59e-05	CbGpPWpGaD
Tretinoin—RXRB—Gene Expression—MAPK3—ovarian cancer	1.87e-05	9.48e-05	CbGpPWpGaD
Tretinoin—RARA—Gene Expression—MAPK3—ovarian cancer	1.87e-05	9.48e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—ABCB1—ovarian cancer	1.85e-05	9.42e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—CAV1—ovarian cancer	1.85e-05	9.4e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—TYMS—ovarian cancer	1.82e-05	9.26e-05	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—ESR1—ovarian cancer	1.82e-05	9.24e-05	CbGpPWpGaD
Tretinoin—NR0B1—Gene Expression—AKT1—ovarian cancer	1.82e-05	9.23e-05	CbGpPWpGaD
Tretinoin—RXRB—Gene Expression—MYC—ovarian cancer	1.81e-05	9.22e-05	CbGpPWpGaD
Tretinoin—RARA—Gene Expression—MYC—ovarian cancer	1.81e-05	9.22e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—FASN—ovarian cancer	1.81e-05	9.21e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—MAPK1—ovarian cancer	1.81e-05	9.19e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—EGFR—ovarian cancer	1.81e-05	9.19e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—SLC5A5—ovarian cancer	1.78e-05	9.06e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.77e-05	8.98e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—SLC2A1—ovarian cancer	1.72e-05	8.75e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—KRAS—ovarian cancer	1.71e-05	8.68e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—BRIP1—ovarian cancer	1.69e-05	8.58e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PPP1CC—ovarian cancer	1.69e-05	8.58e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PIK3CG—ovarian cancer	1.69e-05	8.57e-05	CbGpPWpGaD
Tretinoin—CRABP1—Metabolism—AKT1—ovarian cancer	1.68e-05	8.56e-05	CbGpPWpGaD
Tretinoin—CRABP2—Metabolism—AKT1—ovarian cancer	1.68e-05	8.56e-05	CbGpPWpGaD
Tretinoin—ALDH1A1—Metabolism—AKT1—ovarian cancer	1.68e-05	8.56e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—FASN—ovarian cancer	1.66e-05	8.44e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—CYP1B1—ovarian cancer	1.65e-05	8.38e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.65e-05	8.38e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—YAP1—ovarian cancer	1.64e-05	8.35e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—SLC5A5—ovarian cancer	1.63e-05	8.3e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—CAV1—ovarian cancer	1.62e-05	8.22e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—YAP1—ovarian cancer	1.61e-05	8.16e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—SLC2A1—ovarian cancer	1.58e-05	8.02e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—YAP1—ovarian cancer	1.52e-05	7.71e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—CYP1B1—ovarian cancer	1.51e-05	7.69e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.51e-05	7.68e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.5e-05	7.63e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PIK3CD—ovarian cancer	1.48e-05	7.53e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PIK3CG—ovarian cancer	1.47e-05	7.49e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—CAV1—ovarian cancer	1.47e-05	7.46e-05	CbGpPWpGaD
Tretinoin—RARG—Gene Expression—AKT1—ovarian cancer	1.46e-05	7.44e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PPP2R1A—ovarian cancer	1.46e-05	7.44e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—HRAS—ovarian cancer	1.45e-05	7.38e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.4e-05	7.13e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—YAP1—ovarian cancer	1.39e-05	7.07e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—IL6—ovarian cancer	1.39e-05	7.06e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.38e-05	7e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—ABCB1—ovarian cancer	1.36e-05	6.9e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PPP2R1A—ovarian cancer	1.34e-05	6.82e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—FASN—ovarian cancer	1.34e-05	6.81e-05	CbGpPWpGaD
Tretinoin—RXRG—Gene Expression—AKT1—ovarian cancer	1.34e-05	6.8e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PIK3CG—ovarian cancer	1.34e-05	6.79e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—TYMS—ovarian cancer	1.33e-05	6.78e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.32e-05	6.71e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—SLC5A5—ovarian cancer	1.32e-05	6.7e-05	CbGpPWpGaD
Tretinoin—RARB—Gene Expression—AKT1—ovarian cancer	1.31e-05	6.67e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—FASN—ovarian cancer	1.31e-05	6.65e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PIK3CD—ovarian cancer	1.29e-05	6.58e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PIK3CB—ovarian cancer	1.29e-05	6.56e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—SLC5A5—ovarian cancer	1.29e-05	6.55e-05	CbGpPWpGaD
Tretinoin—RXRA—Developmental Biology—AKT1—ovarian cancer	1.28e-05	6.52e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—CYTB—ovarian cancer	1.27e-05	6.47e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—SLC2A1—ovarian cancer	1.27e-05	6.47e-05	CbGpPWpGaD
Tretinoin—RXRB—Gene Expression—AKT1—ovarian cancer	1.26e-05	6.4e-05	CbGpPWpGaD
Tretinoin—RARA—Gene Expression—AKT1—ovarian cancer	1.26e-05	6.4e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—ABCB1—ovarian cancer	1.25e-05	6.33e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—SLC2A1—ovarian cancer	1.24e-05	6.32e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—FASN—ovarian cancer	1.24e-05	6.29e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.23e-05	6.25e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—TYMS—ovarian cancer	1.22e-05	6.22e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—CYP1B1—ovarian cancer	1.22e-05	6.2e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—SLC5A5—ovarian cancer	1.22e-05	6.18e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.21e-05	6.15e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—CYP1B1—ovarian cancer	1.19e-05	6.06e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—SLC2A1—ovarian cancer	1.18e-05	5.97e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PIK3CD—ovarian cancer	1.18e-05	5.97e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.15e-05	5.85e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—FASN—ovarian cancer	1.13e-05	5.76e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—YAP1—ovarian cancer	1.13e-05	5.75e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PIK3CB—ovarian cancer	1.13e-05	5.74e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—CYP1B1—ovarian cancer	1.13e-05	5.73e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.12e-05	5.69e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PTEN—ovarian cancer	1.12e-05	5.67e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—SLC5A5—ovarian cancer	1.12e-05	5.67e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.11e-05	5.66e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.11e-05	5.66e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PPP2R1A—ovarian cancer	1.08e-05	5.5e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—SLC2A1—ovarian cancer	1.08e-05	5.48e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—CAV1—ovarian cancer	1.08e-05	5.46e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	1.06e-05	5.38e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.05e-05	5.36e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—CYP1B1—ovarian cancer	1.03e-05	5.25e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PIK3CB—ovarian cancer	1.02e-05	5.21e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—ABCB1—ovarian cancer	1e-05	5.11e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	9.99e-06	5.08e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.94e-06	5.05e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—TYMS—ovarian cancer	9.87e-06	5.01e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—CAV1—ovarian cancer	9.85e-06	5.01e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.85e-06	5.01e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—ABCB1—ovarian cancer	9.82e-06	4.99e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PIK3CG—ovarian cancer	9.79e-06	4.98e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PTEN—ovarian cancer	9.75e-06	4.96e-05	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—MAPK3—ovarian cancer	9.72e-06	4.94e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—TYMS—ovarian cancer	9.64e-06	4.9e-05	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—MYC—ovarian cancer	9.46e-06	4.81e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—ABCB1—ovarian cancer	9.28e-06	4.72e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—FASN—ovarian cancer	9.23e-06	4.69e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	9.16e-06	4.66e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.12e-06	4.63e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—TYMS—ovarian cancer	9.11e-06	4.63e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—SLC5A5—ovarian cancer	9.08e-06	4.61e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PIK3CG—ovarian cancer	8.98e-06	4.56e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PTEN—ovarian cancer	8.85e-06	4.5e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—SLC2A1—ovarian cancer	8.77e-06	4.46e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PIK3CD—ovarian cancer	8.61e-06	4.38e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.59e-06	4.36e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—ABCB1—ovarian cancer	8.51e-06	4.32e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—CYP1B1—ovarian cancer	8.41e-06	4.27e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—TYMS—ovarian cancer	8.35e-06	4.25e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—CAV1—ovarian cancer	7.95e-06	4.04e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PIK3CD—ovarian cancer	7.89e-06	4.01e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—PIK3CA—ovarian cancer	7.87e-06	4e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—CAV1—ovarian cancer	7.77e-06	3.95e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PIK3CB—ovarian cancer	7.5e-06	3.81e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—YAP1—ovarian cancer	7.47e-06	3.8e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	7.46e-06	3.79e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.42e-06	3.77e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—CAV1—ovarian cancer	7.34e-06	3.73e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PIK3CG—ovarian cancer	7.24e-06	3.68e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PIK3CG—ovarian cancer	7.08e-06	3.6e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	7.01e-06	3.57e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—ABCB1—ovarian cancer	6.92e-06	3.52e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—PIK3CA—ovarian cancer	6.88e-06	3.5e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PIK3CB—ovarian cancer	6.88e-06	3.5e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—TYMS—ovarian cancer	6.8e-06	3.46e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—CAV1—ovarian cancer	6.73e-06	3.42e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PIK3CG—ovarian cancer	6.69e-06	3.4e-05	CbGpPWpGaD
Tretinoin—RXRA—Gene Expression—AKT1—ovarian cancer	6.56e-06	3.33e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PTEN—ovarian cancer	6.48e-06	3.3e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.43e-06	3.27e-05	CbGpPWpGaD
Tretinoin—CYP4A11—Metabolism—AKT1—ovarian cancer	6.43e-06	3.27e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PIK3CD—ovarian cancer	6.37e-06	3.24e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—PIK3CA—ovarian cancer	6.24e-06	3.17e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PIK3CD—ovarian cancer	6.22e-06	3.16e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PIK3CG—ovarian cancer	6.13e-06	3.12e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—FASN—ovarian cancer	6.09e-06	3.09e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—SLC5A5—ovarian cancer	5.99e-06	3.04e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PTEN—ovarian cancer	5.94e-06	3.02e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PIK3CD—ovarian cancer	5.88e-06	2.99e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—SLC2A1—ovarian cancer	5.78e-06	2.94e-05	CbGpPWpGaD
Tretinoin—CYP2C18—Metabolism—AKT1—ovarian cancer	5.62e-06	2.86e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PIK3CB—ovarian cancer	5.55e-06	2.82e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—CYP1B1—ovarian cancer	5.54e-06	2.82e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—CAV1—ovarian cancer	5.48e-06	2.78e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PIK3CB—ovarian cancer	5.42e-06	2.76e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PIK3CD—ovarian cancer	5.39e-06	2.74e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.23e-06	2.66e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PIK3CB—ovarian cancer	5.12e-06	2.6e-05	CbGpPWpGaD
Tretinoin—RXRA—Metabolism—AKT1—ovarian cancer	5.1e-06	2.59e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PIK3CG—ovarian cancer	4.99e-06	2.54e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	4.92e-06	2.5e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PTEN—ovarian cancer	4.8e-06	2.44e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PIK3CB—ovarian cancer	4.7e-06	2.39e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PTEN—ovarian cancer	4.69e-06	2.38e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—PIK3CA—ovarian cancer	4.57e-06	2.32e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—ABCB1—ovarian cancer	4.57e-06	2.32e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—TYMS—ovarian cancer	4.48e-06	2.28e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PTEN—ovarian cancer	4.43e-06	2.25e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PIK3CD—ovarian cancer	4.39e-06	2.23e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—PIK3CA—ovarian cancer	4.19e-06	2.13e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PTEN—ovarian cancer	4.06e-06	2.06e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PIK3CB—ovarian cancer	3.82e-06	1.94e-05	CbGpPWpGaD
Tretinoin—CYP3A7—Metabolism—AKT1—ovarian cancer	3.74e-06	1.9e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—CAV1—ovarian cancer	3.61e-06	1.84e-05	CbGpPWpGaD
Tretinoin—CYP2A6—Metabolism—AKT1—ovarian cancer	3.43e-06	1.74e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—PIK3CA—ovarian cancer	3.38e-06	1.72e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—PIK3CA—ovarian cancer	3.31e-06	1.68e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PTEN—ovarian cancer	3.3e-06	1.68e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.29e-06	1.67e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—PIK3CA—ovarian cancer	3.12e-06	1.59e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.89e-06	1.47e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—PIK3CA—ovarian cancer	2.86e-06	1.46e-05	CbGpPWpGaD
Tretinoin—CYP2B6—Metabolism—AKT1—ovarian cancer	2.76e-06	1.4e-05	CbGpPWpGaD
Tretinoin—CYP3A5—Metabolism—AKT1—ovarian cancer	2.7e-06	1.37e-05	CbGpPWpGaD
Tretinoin—CYP1A1—Metabolism—AKT1—ovarian cancer	2.55e-06	1.3e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.52e-06	1.28e-05	CbGpPWpGaD
Tretinoin—CYP2C8—Metabolism—AKT1—ovarian cancer	2.34e-06	1.19e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—PIK3CA—ovarian cancer	2.33e-06	1.18e-05	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PTEN—ovarian cancer	2.18e-06	1.11e-05	CbGpPWpGaD
Tretinoin—CYP2C9—Metabolism—AKT1—ovarian cancer	1.9e-06	9.68e-06	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.54e-06	7.81e-06	CbGpPWpGaD
Tretinoin—CYP3A4—Metabolism—AKT1—ovarian cancer	1.26e-06	6.38e-06	CbGpPWpGaD
